As AR mutations are only detected in 13·6–28% of patients with clinical diagnosis of PAIS, it is important for other diagnoses, including NR5A1 mutations, to be considered.3,4 The high testosterone measurement in this case highlights the biochemical variability associated with SF-1/NR5A1 mutations. This evidence concerns the gene NR5A1 and partial androgen insensitivity syndrome.